Vaccines, Blood & Biologics
Resources for You
Discussion Points Email, February 09, 2012 - Ducord
From: Gavin, Denise K
cc: Davidson, Mark;
Subject: RE: Discussion points
Date: Thursday, February 09, 2012 4:58:59 PM
Attachments: (b)(4)review items BLA 125407 2-9-12.doc
Please see the attached informtion request for the -----(b)(4)------ methods and validation (these items were also discussed during 1-6-12 teleconference).
Unless there are questions with the request we would like to wait until 2-22-12 to further discuss these items.
Thank you, denise
From: Gavin, Denise K
Sent: Thursday, February 09, 2012 4:29 PM
To: 'Amanda Parrish, Ph.D.'; Bruce Burnett, Ph.D.
Cc: Davidson, Mark
Subject: Discussion points
Amanda and Bruce,
In order to expedite the review process, we would like to set up two teleconferences to discuss outstanding CMC issues.
Please have relevant quality control folks present if possible to make these discussions more efficient.
1) Review of the CD34 -----(b)(4)------ methods and validations is not possible without additional information.
We would like to set up a meeting on Monday 2-13-12 at 2 pm to give you a list of items we need to work on this review.
2) We would also like to set up a teleconference to discuss the status of all outstanding issues following the midcycle date (2-16-12).
Wed 2-22-12 from 11:30-12:30 works for everyone on our end.
Please let me know if we can schedule discussions on these dates.
Denise K. Gavin, Ph.D. Expert Biologist
Gene Therapy Branch FDA/CBER/OCTGT/DCGT Rockville, MD 20852
"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."
The security of information transmitted through this email can not be guaranteed. Information contained in this email may not reflect the official policy of the FDA and is therefore not legally binding.